TMCnet News

FDA Twitter guidance a gradual step [Medical Marketing and Media]
[September 18, 2014]

FDA Twitter guidance a gradual step [Medical Marketing and Media]


(Medical Marketing and Media Via Acquire Media NewsEdge) FDA'S social media and "cor- recting independent third-party information" draft guidance was greeted as a gradual-but impor- tant-step in the right direction for marketers to deploy their digital and social tools without fear of a Warning Letter.



In its 15-page recommenda- tions for Twitter, the agency says companies should rely on "material fact," as in supported indications from a product's ISI, and that benefits should be juxtaposed with the drug's limitations, contraindications or its relevant patient population- and the most serious side effects should be the most prominent.

In another document, FDA discussed how to handle misin- formation by third parties. "Be non-promotional in nature," the regulator bulleted.


Don't just limit corrections to misinformation that show a prod- uct in a negative light, the guid- ance adds. It recommends firms keep records of these exchanges.

-Kevin McCaffrey (c) 2014 Haymarket Media, Inc.

[ Back To TMCnet.com's Homepage ]